Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis.

Oncotarget - 16 Feb 2016

Fritsche-Guenther Raphaela, Witzel Franziska, Kempa Stefan, Brummer Tilman, Sers Christine, Blüthgen Nils

Abstract excerpt

Targeted therapies within the RAS/RAF/MEK/ERK signalling axis become increasingly popular, yet cross-talk and feedbacks in the signalling network lead to unexpected effects. Here we look systematically into how inhibiting RAF and MEK with clinically relevant inhibitors result in changes in PI3K/AKT activation. We measure the signalling response using a bead-based ELISA, and use a panel of three cell lines, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Blotting, Western

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Colonic Neoplasms

Share to Gene Expression Regulation, Neoplastic

Share to Mutation

Share to Phosphorylation

Share to Proto-Oncogene Proteins B-raf

Share to RNA, Messenger

Source

Open in PubMed Open full text

Identifiers

PMID: 26799289
DOI: 10.18632/oncotarget.6959
PMCID: PMC4884967

Genes

BRAF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis.PMID 26799289Read ↗

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Semantic proximity Read ↗

Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.Semantic proximity Read ↗

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.Semantic proximity Read ↗

Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapySemantic proximity Read ↗

Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways.Semantic proximity Read ↗

Hidden Targets in RAF Signalling Pathways to Block Oncogenic RAS SignallingSemantic proximity Read ↗

Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors.Semantic proximity Read ↗

Mechanism and consequences of RAF kinase activation by small-molecule inhibitorsSemantic proximity Read ↗

BRAF mutation predicts sensitivity to MEK inhibition.Semantic proximity Read ↗

Targeting the MAPK–RAS–RAF signaling pathway in cancer therapySemantic proximity Read ↗

Raf-interactome in tuning the complexity and diversity of Raf function.Semantic proximity Read ↗

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.